- Home
- MAGN vs YMAB Comparison
MAGN vs YMAB Comparison
Compare MAGN & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAGN
- YMAB
- Stock Information
- Founded
- MAGN 1864
- YMAB 2015
- Country
- MAGN United States
- YMAB United States
- Employees
- MAGN N/A
- YMAB N/A
- Industry
- MAGN Paper
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MAGN Basic Materials
- YMAB Health Care
- Exchange
- MAGN Nasdaq
- YMAB Nasdaq
- Market Cap
- MAGN 422.2M
- YMAB 386.7M
- IPO Year
- MAGN N/A
- YMAB 2018
- Fundamental
- Price
- MAGN $13.29
- YMAB $8.53
- Analyst Decision
- MAGN Hold
- YMAB Buy
- Analyst Count
- MAGN 1
- YMAB 10
- Target Price
- MAGN $14.00
- YMAB $13.91
- AVG Volume (30 Days)
- MAGN 550.3K
- YMAB 2.0M
- Earning Date
- MAGN 08-06-2025
- YMAB 08-08-2025
- Dividend Yield
- MAGN N/A
- YMAB N/A
- EPS Growth
- MAGN N/A
- YMAB N/A
- EPS
- MAGN N/A
- YMAB N/A
- Revenue
- MAGN $2,919,000,000.00
- YMAB $85,385,000.00
- Revenue This Year
- MAGN $47.87
- YMAB N/A
- Revenue Next Year
- MAGN $4.76
- YMAB $13.97
- P/E Ratio
- MAGN N/A
- YMAB N/A
- Revenue Growth
- MAGN 34.21
- YMAB N/A
- 52 Week Low
- MAGN $10.39
- YMAB $3.55
- 52 Week High
- MAGN $26.78
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- MAGN 54.31
- YMAB 81.62
- Support Level
- MAGN $12.35
- YMAB $8.50
- Resistance Level
- MAGN $13.26
- YMAB $8.54
- Average True Range (ATR)
- MAGN 0.58
- YMAB 0.02
- MACD
- MAGN 0.03
- YMAB 0.00
- Stochastic Oscillator
- MAGN 83.09
- YMAB 80.00
About MAGN Magnera Corporation Common Stock
Magnera Corp formerly Glatfelter Corporation manufactures and sells a variety of paper and fiber products. The company's reportable segments are; Composite Fibers, Spunlace. and Airlaid Materials. The Airlaid Materials segment which is also its key revenue generating segment, is a supplier of cellulose-based airlaid nonwoven materials used to manufacture consumer products for end-user markets. The Airlaid Materials segment produces materials used in feminine hygiene, specialty wipes, tabletop, home care, and other consumables. Geographically, the company derives majority of its revenue from Americas and rest from Europe, Middle East, Africa and Asia Pacific markets.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.